Observational, Postmarketing Surveillance Study of Spinraza Injection

See also
Status	Clinical Trial	Phase
Completed	`NCT00533221` - Pilot Study of Growth Hormon to Treat SMA Typ II and III	Phase 2
Completed	`NCT02908685` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants	Phase 2
Recruiting	`NCT05575011` - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115	Phase 1
Completed	`NCT05073133` - Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)	Phase 4
Terminated	`NCT02240355` - A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)	Phase 1
Recruiting	`NCT05042921` - Pediatric Spinal Muscular Atrophy (SMA) China Registry
Completed	`NCT04419233` - Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
Recruiting	`NCT05861986` - A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy	Phase 4
Completed	`NCT00466349` - International SMA Patient Registry
Completed	`NCT03920865` - A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function	Phase 1
Recruiting	`NCT05481164` - Newborn Screening for Spinal Muscular Atrophy
Completed	`NCT04089566` - Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy	Phase 3
Recruiting	`NCT05861999` - A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy	Phase 4
Recruiting	`NCT05755451` - Natural History of SMA
Active, not recruiting	`NCT01233817` - Progressive Strength Training in Spinal Muscular Atrophy	N/A
Active, not recruiting	`NCT05618379` - Adult Spinal Muscular Atrophy (SMA) China Registry
Active, not recruiting	`NCT04488133` - A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec	Phase 4
Completed	`NCT03781479` - Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients	Phase 2
Completed	`NCT00568802` - A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients	Phase 1/Phase 2
Completed	`NCT00568698` - A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients	Phase 1/Phase 2

NCT number	NCT04317794
Study type	Observational
Source	Biogen
Contact	US Biogen Clinical Trial Center
Phone	866-633-4636
Email	clinicaltrials@biogen.com
Status	Recruiting
Phase
Start date	July 2, 2019
Completion date	July 1, 2027

Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) — STANDARD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms